Genitourinary/Renal

Clinical Trial NameClinical Trial Full TitlePrincipal InvestigatorProject site statusClinical trials gov number
AGS-16C3F-15-3A Multi-center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell CarcinomaHotte, Dr Sebastien OpenNCT02639182
FRACTION-RCCA Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in
Participants with Advanced Renal Cell Carcinoma
Hotte, Dr Sebastien OpenNCT02996110
MK-3475-426A Phase III Randomized, Open-label, Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-426)Hotte, Dr Sebastien OpenNCT02853331
CO39303 A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL TESTING IPATASERTIB PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE, RELATIVE TO PLACEBO PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE IN PATIENTS WITH ASYMPTOMATIC OR MILDLY SYMPTOMATIC METASTATIC CASTRATE-RESISTANT PROSTATE CANCER WITH PTEN-LOSS (PTEN DIAGNOSTIC POSITIVE) TUMORSMukherjee, Dr SomOpenNCT03072238
PROfoundA Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment with a New Hormonal Agent and Have
Homologous Recombination Repair Gene Mutations (PROfound)
Hotte, Dr Sebastien OpenNCT02987543
WO39210A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) AS ADJUVANT THERAPY IN PATIENTS WITH PD-L1-SELECTED RENAL CELL CARCINOMA AT INTERMEDIATE TO HIGH RISK OF DEVELOPING METASTASIS FOLLOWING NEPHRECTOMYHotte, Dr Sebastien OpenNCT03024996
IND.223A Phase II Study of Palbociclib, A CDK4/6 Inhibitor, in Patients with Metastatic Castration-Resistant Prostate CancerMukherjee, Dr SomOpenNCT02905318
OCOG-2013-PETMUSEImpact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder StagingMukherjee, Dr SomOpenNCT02462239
OCOG-2016-MISTERAssessment of New Molecular Imaging Strategies for Prostate Cancer: Predictive Value of Established and Novel PET Radiotracers in Castration-Resistant Prostate CancerHotte, Dr Sebastien OpenNCT02813226
OZM-053A Phase II, Multi-Centre Study, of Stereotactic Radiotherapy for Oligo-Progression in Renal Cell Cancer Patients Receiving 1st Line Sunitinib TherapySwaminath, Dr AnandOpenNCT02019576
OZM-054A Phase II, randomized, multi-center study of cabazitaxel versus abiraterone or enzalutamide in poor prognosis-metastatic castration-resistant prostate cancerHotte, Dr Sebastien OpenNCT02254785
PACEPACE - International Randomized Study of Laparoscopic Prostatectomy vs Robotic Radiosurgery and Conventionally Fractionated Radiotherapy vs Radiosurgery for Early Stage Organ-Confined Prostate CancerDayes, Dr IanOpenNCT01584258
TOPCOPTOward Personalizing Care for Older men with mCRPC - understanding and predicting treatment toxicities (the TOPCOP study)Hotte, Dr Sebastien OpenNCT02512185
TRITON2A Multicenter, Open-label Phase 2 Study of Rucaparib in
Patients with Metastatic Castration-resistant Prostate Cancer Associated
with Homologous Recombination Deficiency
Hotte, Dr Sebastien OpenNCT02952534
WO30070A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, PARTIAL -BLIND STUDY OF ATEZOLIZUMAB (ANTI-PDL1 ANTIBODY) MONOTHERAPY AND IN COMBINATION WITH PLATIMUN BASED THERAPY VERSUS PLATINUM BASED THERAPY PLUS PLACEBO IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMAMukherjee, Dr SomOpenNCT02807636
IND.232A Phase II Study of Durvalumab With or Without Tremelimumab in Patients With Metastatic castration Resistant Prostate CancerHotte, Dr Sebastien On holdNCT02788773
Prostate HBINon-Targeted Low Dose Radiotherapy For Recurrent Prostate CancerDayes, Dr IanOn holdNCT03196778
Download PDF